Abstract:12129 Background: The delineation of cytokine release syndrome (irCRS) from sepsis and its transition to compensatory anti-inflammatory response syndrome (irCARS) is crucial during ICI therapy for personalized care. Methods: We conducted an extensive biological and immune profiling on PBMC and serum from 38 oncology patients with various irCRS grades, including immune-related hemophagocytic lymphohistiocytosis irHLH (n=9) and sepsis during ICI treatment (n=8). Results: Our results show a dominant Th1 response in irCRS. Early markers of irCRS increased progressively with clinical severity in different grades, especially CXCL9, CXCL10 and IFN-γ levels. Starting with low-grade (G) (G1 and 2), a concomitant irCARS response was detected, characterized by an initial increase in IL-1RA and a significant upregulation of IL-10 specifically in G4. 3 subclusters with different overall survival (OS) and cytokine profiles were identified using routine biomarkers. Cluster 1 (C1, n=7) and Cluster 2 (C2, n=17) showed a 2-year OS of 100% and 48.49%, respectively (HR=4.025 [95% CI = 1.052-15.39], p=0.0419) and differed with higher levels of CCL3/11, CXCL10 and Il-1RA. Cluster 3 (C3, n=3) had the lowest OS, 6-month OS of 0%, and a distinct biological profile with highest levels of CXCL8/12/13, IL1-RA, IL-6, IL-21, HGF, significantly different from C1 (HR=111.4 [95% CI=6.63-1871], p=0.0011) and C2 (HR=30.04 [95% CI=2.686-335.9], p=0.0256). In 12 patients with severe irCRS (G3 and 4) and refractory to steroids, treatment with tocilizumab (TCZ) resulted in 100% resolution. In irHLH patients (n=9), the clusters retained their prognostic impact. Similarly, in irHLH with poor prognosis (irHLH cluster 3, n=3), high levels of CXCL8/12/13, IL-6 and IL-21 were identified. 13 patients with sepsis-like symptoms (irHLH, n=8; or sepsis during ICI, n=5) showed distinct cytokine and immune cell profiles. irHLH showed elevated IL-1-RA, IL-10, IL-18, IFN-γ, CXCL9/10, CCL2/3/4 while sepsis was characterized by increased IL-7. In irHLH, higher HLA-DR+/CD38+ populations were seen in T cells, monocytes, DCs and NK cells. There was significant CD62L downregulation in neutrophils during sepsis. Our decision tree using ferritin, EGF, IL-6 and leukocytes effectively discriminated irHLH from sepsis and G3 irCRS. High CXCL-9 levels predicted the diagnosis and severity of irHLH more accurately than the conventional HScore. Conclusions: We've identified a panel of biomarkers associated with OS. CXCL9 emerges as a superior marker, outperforming HScore. The successful treatment with TCZ underscores the importance of targeted interventions. Our decision tree enhances diagnostic accuracy for sepsis-like symptoms, aiding in the differentiation between irCRS, irHLH, and sepsis. This supports the optimal implementation of personalized strategies.

The Pivotal Role of Immune Functional Assays in Deciphering Immune Function Alterations

Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study

Surviving septic patients endotyped with a functional assay demonstrate active immune responses

Integrated clustering of multiple immune marker trajectories reveals different immunotypes in severely injured patients

Comparison of whole blood cytokine immunoassays for rapid, functional immune phenotyping in critically ill patients with sepsis

Use of Immune Profiling Panel to assess the immune response of septic patients for prediction of worsening as a composite endpoint

Functional immune reconstitution early after allogeneic haematopoietic cell transplantation: A comparison of pre- and post-transplantation cytokine responses in stimulated whole blood

The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients

Adverse outcomes and an immunosuppressed endotype in septic patients with reduced IFN-γ ELISpot

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.

Predicting Organ Dysfunction in Septic and Critically Ill Patients: A Prospective Cohort Study Using Rapid Ex Vivo Immune Profiling

Comparison of host immune responses to LPS in human using an immune profiling panel, in vivo endotoxemia versus ex vivo stimulation

An immune dysfunction score for stratification of patients with acute infection based on whole-blood gene expression

Development and optimization of a diluted whole blood ELISpot assay to test immune function

- Immune biomarkers in psychiatric illness: Findings from the biomarker subgroup of the NSAS Brain-Immune Interactions Workshop

Time-Dependent Variation in Immunoparalysis Biomarkers Among Patients with Sepsis and Critical Illness

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy

High-dimensional longitudinal immune profiling uncovers a dual role of the CXCL9/CXCR3, CXCL13/CXCR5, and CCL11/CCL3 axis in the coupling of immune-related adverse events to immune checkpoint inhibitor response.

Combining SARS‐CoV‐2 interferon‐gamma release assay with humoral response assessment to define immune memory profiles

Abstract 90: In vitro functional evaluation of immuno-oncology drug candidates in customized bioassays